Engen Phillip A, Zaferiou Antonia, Rasmussen Heather, Naqib Ankur, Green Stefan J, Fogg Louis F, Forsyth Christopher B, Raeisi Shohreh, Hamaker Bruce, Keshavarzian Ali
Division of Gastroenterology, Department of Internal Medicine, Rush University Medical Center, Chicago, IL, United States.
Department of Biomedical Engineering, Stevens Institute of Technology, Hoboken, NJ, United States.
Front Neurol. 2020 Sep 8;11:978. doi: 10.3389/fneur.2020.00978. eCollection 2020.
Emerging evidence suggests intestinal microbiota as a central contributing factor to the pathogenesis of Relapsing-Remitting-Multiple-Sclerosis (RRMS). This novel RRMS study evaluated the impact of fecal-microbiota-transplantation (FMT) on a broad array of physiological/clinical outcomes using deep metagenome sequencing of fecal microbiome. FMT interventions were associated with increased abundances of putative beneficial stool bacteria and short-chain-fatty-acid metabolites, which were associated with increased/improved serum brain-derived-neurotrophic-factor levels and gait/walking metrics. This proof-of-concept single-subject longitudinal study provides evidence of potential importance of intestinal microbiota in the pathogenesis of MS, and scientific rationale to help design future randomized controlled trials assessing FMT in RRMS patients.
新出现的证据表明，肠道微生物群是复发缓解型多发性硬化症（RRMS）发病机制的一个核心促成因素。这项关于RRMS的新研究使用粪便微生物组的深度宏基因组测序，评估了粪便微生物群移植（FMT）对一系列生理/临床结果的影响。FMT干预与假定的有益粪便细菌和短链脂肪酸代谢物丰度增加有关，这与血清脑源性神经营养因子水平升高/改善以及步态/行走指标有关。这项概念验证单受试者纵向研究提供了证据，证明肠道微生物群在MS发病机制中的潜在重要性，并为帮助设计未来评估RRMS患者FMT的随机对照试验提供了科学依据。
